173 related articles for article (PubMed ID: 25301403)
21. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
[TBL] [Abstract][Full Text] [Related]
22. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer.
Losi L; Bouzourene H; Benhattar J
Oncol Rep; 2007 May; 17(5):1095-9. PubMed ID: 17390050
[TBL] [Abstract][Full Text] [Related]
23. Specific genomic aberrations in primary colorectal cancer are associated with liver metastases.
Bruin SC; Klijn C; Liefers GJ; Braaf LM; Joosse SA; van Beers EH; Verwaal VJ; Morreau H; Wessels LF; van Velthuysen ML; Tollenaar RA; Van't Veer LJ
BMC Cancer; 2010 Dec; 10():662. PubMed ID: 21126340
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
[TBL] [Abstract][Full Text] [Related]
25. Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases.
Kern A; Taubert H; Scheele J; Rudroff C; Mothes H; Kappler M; Bartel F; Richter KK
Int J Oncol; 2002 Aug; 21(2):243-9. PubMed ID: 12118317
[TBL] [Abstract][Full Text] [Related]
26. The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.
Geva R; Shamai S; Brazowsky E; Paoulas M; Ben-Haim M; Johnstone E; Alex B; Shacham-Shmueli E
Cancer Invest; 2015 Apr; 33(4):89-97. PubMed ID: 25723812
[TBL] [Abstract][Full Text] [Related]
27. SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases.
López-Gómez M; Moreno-Rubio J; Suárez-García I; Cejas P; Madero R; Casado E; Jiménez A; Sereno M; Gómez-Raposo C; Zambrana F; Merino M; Fernández-Luengas D; Feliu J
Clin Transl Oncol; 2015 Feb; 17(2):133-8. PubMed ID: 25060566
[TBL] [Abstract][Full Text] [Related]
28. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
Matsuyama R; Togo S; Shimizu D; Momiyama N; Ishikawa T; Ichikawa Y; Endo I; Kunisaki C; Suzuki H; Hayasizaki Y; Shimada H
Int J Cancer; 2006 Jul; 119(2):406-13. PubMed ID: 16477629
[TBL] [Abstract][Full Text] [Related]
29. Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
Nakamoto RH; Uetake H; Iida S; Kolev YV; Soumaoro LT; Takagi Y; Yasuno M; Sugihara K
Jpn J Clin Oncol; 2007 Sep; 37(9):679-85. PubMed ID: 17846040
[TBL] [Abstract][Full Text] [Related]
30. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
31. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
Gentner B; Wein A; Croner RS; Zeittraeger I; Wirtz RM; Roedel F; Dimmler A; Dorlaque L; Hohenberger W; Hahn EG; Brueckl WM
Anticancer Res; 2009 Jan; 29(1):67-74. PubMed ID: 19331134
[TBL] [Abstract][Full Text] [Related]
32. Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2009 Apr; 34(4):1147-53. PubMed ID: 19287974
[TBL] [Abstract][Full Text] [Related]
33. Whole genome analysis for liver metastasis gene signatures in colorectal cancer.
Ki DH; Jeung HC; Park CH; Kang SH; Lee GY; Lee WS; Kim NK; Chung HC; Rha SY
Int J Cancer; 2007 Nov; 121(9):2005-2012. PubMed ID: 17640062
[TBL] [Abstract][Full Text] [Related]
34. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.
Amara S; Chaar I; Khiari M; Ounissi D; Weslati M; Boughriba R; Hmida AB; Bouraoui S
Cancer Biomark; 2015; 15(6):869-79. PubMed ID: 26406413
[TBL] [Abstract][Full Text] [Related]
35. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
Wang AZ; Zhu ZZ; Cong WM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):168-71. PubMed ID: 18393238
[TBL] [Abstract][Full Text] [Related]
36. Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors.
Oxboel J; Binderup T; Knigge U; Kjaer A
Oncol Rep; 2009 Mar; 21(3):769-75. PubMed ID: 19212638
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of miR-17 is correlated with liver metastasis in colorectal cancer.
Lai H; Zhang J; Zuo H; Liu H; Xu J; Feng Y; Lin Y; Mo X
Medicine (Baltimore); 2020 Feb; 99(9):e19265. PubMed ID: 32118734
[TBL] [Abstract][Full Text] [Related]
39. Tropism between hepatic and pulmonary metastases in colorectal cancers.
Kim SH; Choi SJ; Park JS; Lee J; Cho YB; Kang MW; Lee WY; Choi YS; Kim HK; Han J; Chun HK; Kim J
Oncol Rep; 2012 Aug; 28(2):459-64. PubMed ID: 22664832
[TBL] [Abstract][Full Text] [Related]
40. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
